Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMC558445
- Development stage
- Phase 1
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TMC558445 is an investigational **small molecule cytochrome P450 (CYP) inhibitor** developed for use as a standalone pharmacokinetic booster, particularly to increase the plasma levels of other antiretroviral agents such as the HIV protease inhibitor TMC310911 and possibly Darunavir. It has been studied in healthy volunteers for its safety, tolerability, and pharmacokinetic properties, focusing on dosage escalation and its pharmacokinetic enhancing effects. This agent was developed by Tibotec Pharmaceuticals and subsequently associated with Janssen and Janssen Global Services. Its development for HIV infection reached Phase 1 clinical testing but has since been discontinued[1][3][5][7].
- Other names
- TMC-558445TMC558445TMC 558445
02
Targets
CYP3A4 (Cytochrome P450 3A4)Cyp (Cyclophilin family)
Beyond the preview
Go deeper on TMC558445.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMC558445.